🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🎯Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era 📍 Published in @Medicina_MDPI 🔗 doi.org/10.3390/medici… pubmed.ncbi.nlm.nih.gov/40428882/ In this comprehensive review, we explore how

Colleagues at #ASCO25 Join us for the GUARD Symposium🇪🇸 featuring interactive workshops where experts collaboratively discuss real-world genitourinary cancer cases. REGISTER👉 events.tacticsmd.net/guard-internat… ⭐️FREE VIRTUAL Admission for LMIC's & LATAM Colleagues⭐️ This meeting

1/2 ctDNA data for durvalumab+NAC in MIBC from NIAGARA #ASCO25. 57%,22%,9% of pts are ctDNA +ve at baseline/post NAC/post surgery. Poor outcomes for cDNA+ve occur at each time point (HR 0.4,0.3,0.1 respectively). Chemo cleared the ctDNA in most pts & was ⬆️13% with durvalumab

2/2 ctDNA+ status post chemo was associated with ⬇️⬇️ likelihood of pCR at surgery. ~30% of ctDNA-ves at baseline relapsed vs 65% of +ves. Baseline status did not define pts that benefited from durva. ctDNA-ve pts post surgery(90%) also appeared to benefit from durva. #ASCO25

3/3 The ctDNA biomarker is not perfect (-ves still relapse post surgery) & there was no 3rd arm in NIAGARA with neoadjuvant D+NAC alone. Therefore ctDNA & pCR cannot determine the importance of adjuvant durva. A 3rd arm needed 1500 pts which seemed too many back in 2016 #ASCO25

🤩Privileged to be co-author in this paper on the CREST trial published at Nature Medicine with Tom Powles Matt Galsky Joan Palou Redorta Evanguelos Xylinas Alberto Briganti among others 🙌🏼Thrilled to be part of an eventual paradigm shift in #NMIBC after 50 years 👣This is only the

Brutales resultados del impacto de la hora de administración de la inmunoterapia en estudio randomizado. Pocos fármacos han demostrado datos tan contundentes. Debemos reconsiderar administrar la inmuno antes de las 15.00 en todos los pacientes, excepto fuera un ensayo clínico.

Just back from #ASCO25, where I joined an ecancer roundtable on recent updates in renal cell carcinoma. Great to exchange views with highly experienced colleagues in the field. 🎥 Video here: player.vimeo.com/video/10898609… Guillermo de Velasco Michael Serzan, MD Javier Puente #GUcancer #RenalCancer

🤔 Still thinking about the fantastic #KidneyCancer program from #ASCO25? 🎙️Join international panel of experts Alessandro Rametta 🇮🇹, Guillermo de Velasco 🇪🇸, Javier Puente 🇪🇸 as we discuss how impactful RCC data influences practice today and research tomorrow! 🔗 shorturl.at/yXAZr 👥

🚨 ¡Recordatorio para jóvenes adjuntos! El 25 de junio tienes una cita con el GUARD Mentorship Meeting: una jornada pensada para inspirarte y motivarte desde el primer minuto. 🗓 Consulta el programa e inscríbete aquí 👉 guardconsortium.org/actividad/jorn…

🚨Disponible el 3r Episodio de la 1ª. Ed. #TooMoreUrotelio #CáncerUrotelial ¿Un punto de inflexión en NMIBC agresivo? Javier Puente y Félix Guerrero-Ramos repasan los últimos avances: 🔹Nuevos datos (Estudio CREST) 🔹BCG + sasanlimab, ¿para quién y cómo manejar toxicidad?  🔹Claves para

Join us for the GUARD Symposium🇪🇸 featuring interactive workshops where experts collaboratively discuss real-world genitourinary cancer cases. REGISTER👉 events.tacticsmd.net/guard-internat… ⭐️FREE VIRTUAL Admission for LMIC's & LATAM Colleagues⭐️ Here is our Colleague Dr. Felipe Couñago PhD🇪🇸 with

So proud of my team !!! 😎European Urology Oncology we have a rise of one point of our impact factor over the last year. Congrats for the great achievement Renu Eapen Riccardo Campi Alicia Morgans, MD, MPH Elena Castro Ashish M. Kamat, MD, MBBS Jeremy Teoh Laura Marandino Ploussard Guillaume we deliver for European Association of Urology (EAU)

¡Gracias a todos por el éxito del Mentorship Meeting! Y en especial a Pedro C Barata, MD MSc FACP por su apoyo y su implicación. Seguro que muchos futuros proyectos de GUARD Consortium salen de esta reunión. ¡Os esperamos mañana en el GUARD International Symposium!

🌟🔵 Redefining metastatic hormone-sensitive prostate cancer Javier Puente OncoAlert #GUARDSymposium2025 🔹 Timing & burden define prognosis in mHSPC 🔹 Drug selection = disease + patient + regimen factors 🔹 Triplet therapy: 94% support in high-volume, fit patients 🔹 APCCC vote:

FGFR inhibition in FGFR3 altered UC doesn’t get the attention it deserves #GUARDSymposium2025 Its data platinum refractory UC is similar to EV. It’s used in late disease. Sadly there are no R3s 1st line or combo studies. The survey below shows enthusiasm post EVP OncoAlert

With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to say ‘pick one and use it well’. #GUARDSymposium2025 Ipi/nivo is less good at getting initial control but has less long term toxicity. Brian Rini, MD OncoAlert

LIVE Day TWO #GUARDSymposium2025 Presentation by Dr. Matt Galsky🇺🇸 How to select patients in whom we preserve the bladder without local treatment? Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos Mario AlvarezMaestro Urbano Anido Javier Molina Cerrillo David Lorente

🚨Quedan 10 días para la II Edición de nuestro masterclass en cáncer de vejiga . ➡️Link para inscripción online y presencial: eira.meetingpharma.com/projects/iimee…

Gem/cis/durvalumab is approved in the EU for muscle invasive bladder cancer (NIAGARA study). It’s the only immune therapy study in the adjuvant or neoadjuvant setting with significant OS. ⬆️ pCR and EFS support this appr OncoAlert Annals of Oncology astrazeneca.com/media-centre/p…